THX Pharma Appoints Sophie Jacq Lapointe to Board of Directors

THX Pharma, a biopharmaceutical company based in Lyon, France, has appointed Sophie Jacq Lapointe to its Board of Directors. Lapointe brings over two decades of experience in the pharmaceutical and biotechnology sectors, having held leadership roles at prominent companies such as Roche, Sanofi, and Ipsen. Her notable accomplishments include successful product launches, notably Dupixent® at Sanofi Genzyme.

This appointment aligns with THX Pharma's strategy to accelerate the commercialization of its drug candidates for rare diseases. CEO Mathieu Charvériat expressed confidence in Lapointe's expertise, particularly in market access and corporate strategy, to guide the company's future growth.

Lapointe, a graduate of ESSEC Business School with further specializations, is enthusiastic about contributing to THX Pharma's mission of advancing treatment accessibility for patients.